Ruben

[Isabella Soprano @Fourty35]

Es un película de Oscar, pero no de Oscar a mejor película de habla no inglesa. No, de Oscar a película principal.
Se mea en Parásitos, en La Odisea, en CODA, en Nomadland, en Anora y en el 95% de todo el cine premiado en Hollywood en los últimos 15 años.

[Ruben @ElRubenko]

@majorajay @MazieTsangMD @DiMengyang @dr_supreetkaur @priyankapophali @PallawiTorkaMD Makes sense! Which specific combos are you evaluating? It'd be interesting to see some TT analysis in more challenging areas, like CNS lymphoma.

[Ruben @ElRubenko]

@majorajay @michaelwangmd @tobyeyre82 Thought this was developed in combination w BTKi (sympatico fashion). Its intriguing how BCL2i monotherapy seems less active after previous BTKi exposure un MCL (cross ressistance?), unlike CLL

[Ruben @ElRubenko]

@majorajay @JuanAlderuccio @AsaadTrabolsi Love the potential of this regimen. Also intrigued to know if there was a differential effect on nonGCB subtype

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🚨🚨Breaking News:

The FDA has eliminated the Risk Evaluation and Mitigation Strategy (REMS) for all currently approved BCMA- and CD19-directed autologous CAR T therapies (including Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta) 

What does this mean?

1) Easier Access: Hospitals no longer need REMS certification
2) Streamlined Care: Updated labeling requires monitoring patients daily for one week post-infusion and restricting activities such as driving and travel proximity for two weeks  .
3) Less Burden on Clinics: Simplifies administration, especially in rural or community settings .

This is the beginning to start administering CAR-T to pts in community Clinics

@US_FDA @FDAOncology #mmsm #myeloma #MedEd #medtwitter @USMIRCNEWS @Larvol @medicalwatchBC @OncoAlert

[Ruben @ElRubenko]

@majorajay And way more SPMs w GIV?

[Ruben @ElRubenko]

@Eddie_Cliff Is there any COO subgroup analysis for Starglo?

[Ruben @ElRubenko]

@majorajay @PallawiTorkaMD @DunleavyKieron Is this HTB FL? Surprised there's a similar phase 2 with SC mosun in HTB FL (MorningSun, ASCO) with a more prolonged schedule (17 cycles, 1 year) and optional maintenance thereafter. Which schedule are they pursuing in 1L?

[Ruben @ElRubenko]

@dgermain21 @Eddie_Cliff Looks very convincing to me. Quite surprised by how this differential activity of Pola for non-GCB is somehow neglected.

[Ruben @ElRubenko]

@glimelius @majorajay @tobyeyre82 Looks very attractive, specially given as FD for elderly population. Are you considering rechallenging at relapse? Congratulations on this trial, are you planning a formal publication?

[Ruben @ElRubenko]

@majorajay @glimelius @tobyeyre82 Thank you! Love the FD strategy and the comprehensive translational data. Looks very effective and reassuring to see no substantial infection burden despite the somehow intensive rituximab schedule. Perhaps more attractive than ECHO approach

[Ruben @ElRubenko]

@graham74GC I dont think there's an apetite for continuous therapy frontline. Lot of cardiac AEs in this one.

[Ruben @ElRubenko]

@glimelius Very surprising and scary! You have any speculation about the relationship with the MCL context?

[Ruben @ElRubenko]

@JhaveriKhushali Those who stopped treatment could be rechallenged w. Acala at progression? Very cool study

[Ruben @ElRubenko]

@majorajay Also got positive opinion by the EMA. Not appealing for me, beyond the lack of OS benefit, how you treat those pts who progress after acala-BR? (Pirto here only licensed for 3L+). I wonder if designed with a FD strategy maybe more attractive .

[Ruben @ElRubenko]

@majorajay Any QoL data?

[Ruben @ElRubenko]

@ContactoAmeh Se podrá ver en diferido? Felicidades por la iniciativa, luce increíble

[Nico Gagelmann @NicoGagelmann]

Never apologize for your background, your language, or your status.